Peptide T TFA
Based on 1 publication(s) in Google Scholar
Peptide T (TFA) is an octapeptide from the V2 region of HIV-1 gp120. Peptide T is a ligand for the CD4 receptor and prevents binding of HIV to the CD4 receptor.
For research use only. We do not sell to patients.
- CAS No.: 1610056-01-3
- Formula: C37H56F3N9O18
- Molecular Weight:971.89
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Peptide T TFA
More
Biological Activity
|
HIV-1 |
Peptide T acts to block viral entry as it inhibits in the MAGI cell assay and blocks infection in the luciferase reporter assay using HIV virions pseudotyped with ADA envelope. Peptide T selectively inhibits HIV replication using chemokine receptor CCR5 compared to CXC4[2]. Peptide T at 10-8 M induces IL-10 production by the human Th2 cell line and PBMC. Also peptide T at 10-9 M concentration significantly inhibits IFN-g production by PBMC[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 1610056-01-3
-
Molecular Weight 971.89
-
Formula C37H56F3N9O18
-
Sequence
Ala-Ser-Thr-Thr-Thr-Asn-Tyr-Thr
-
Sequence Shortening
ASTTTNYT
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Cancer Res
TRAPPC4 Promotes GPX4 Stability to Drive Ferroptosis Resistance and Tumor Progression in Head and Neck Squamous Cell Carcinoma. [Abstract]2026 Jul 15;86(14):3436-3458. PMID: 41974002
Protocol
Peripheral blood mononuclear cells are stimulated with PHA (5 mg/mL) along with various concentrations of peptide T (10-6-10-12 M) for 48 h at 37°C. Supernatants are collected and frozen until analysis[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Rats[4]
Peptide T (125, 250, 500, 800 μg) is randomly given subcutaneously to Female Lewis rats aged 6-8 weeks in the hind foot flanks in a final volume of 0.2 mL. Control animals receive the same volume of saline alone[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
References
[1]. Ruff MR, et al. Peptide T[4-8] is core HIV envelope sequence required for CD4 receptor attachment. Lancet. 1987 Sep 26;2(8561):751. [Content Brief]
[2]. Ruff MR, et al. Peptide T inhibits HIV-1 infection mediated by the chemokine receptor-5 (CCR5). Antiviral Res. 2001 Oct;52(1):63-75. [Content Brief]
[3]. Raychaudhuri SP, et al. Immunomodulatory effects of peptide T on Th 1/Th 2 cytokines. Int J Immunopharmacol. 1999 Sep;21(9):609-15. [Content Brief]
[4]. Sáez-Torres I, et al. Peptide T does not ameliorate experimental autoimmune encephalomyelitis (EAE) in Lewis rats. Clin Exp Immunol. 2000 Jul;121(1):151-6. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Peptide T TFA Related Classifications
HY-P0272A Related Classifications
Powered by Bioz